b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Data-Review" Owner="NLM">\n        <PMID Version="1">32233491</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>04</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1543-8392</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>17</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>May</Month>\n                        <Day>04</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Molecular pharmaceutics</Title>\n                <ISOAbbreviation>Mol. Pharm.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Synthesis and Analysis of <sup>64</sup>Cu-Labeled GE11-Modified Polymeric Micellar Nanoparticles for EGFR-Targeted Molecular Imaging in a Colorectal Cancer Model.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1470-1481</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.9b01043</ELocationID>\n            <Abstract>\n                <AbstractText>Polymeric micellar nanoparticles represent versatile and biocompatible platforms for targeted drug delivery. However, tracking their biodistribution, stability, and clearance profile in vivo is challenging. The goal of this study was to prepare surface-modified micelles with peptide GE11 for targeting the epidermal growth factor receptor (EGFR). In vitro fluorescence studies demonstrated significantly higher internalization of GE11 micelles into EGFR-expressing HCT116 colon cancer cells versus EGFR-negative SW620 cells. Azo coupling chemistry of tyrosine residues in the peptide backbone with aryl diazonium salts was used to label the micelles with radionuclide <sup>64</sup>Cu for positron emission tomography (PET) imaging. In vivo analysis of <sup>64</sup>Cu-labeled micelles showed prolonged blood circulation and predominant hepatobiliary clearance. The biodistribution profile of EGFR-targeting GE11 micelles was compared with nontargeting HW12 micelles in HCT116 tumor-bearing mice. PET revealed increasing tumor-to-muscle ratios for both micelles over 48 h. Accumulation of GE11-containing micelles in HCT116 tumors was higher compared to HW12-decorated micelles. Our data suggest that the efficacy of image-guided therapies with micellar nanoparticles could be enhanced by active targeting, as demonstrated with cancer biomarker EGFR.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Paiva</LastName>\n                    <ForeName>Igor</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mattingly</LastName>\n                    <ForeName>Stephanie</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wuest</LastName>\n                    <ForeName>Melinda</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Leier</LastName>\n                    <ForeName>Samantha</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vakili</LastName>\n                    <ForeName>Mohammad Reza</ForeName>\n                    <Initials>MR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Weinfeld</LastName>\n                    <ForeName>Michael</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lavasanifar</LastName>\n                    <ForeName>Afsaneh</ForeName>\n                    <Initials>A</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5108-7124</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wuest</LastName>\n                    <ForeName>Frank</ForeName>\n                    <Initials>F</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6705-6450</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>04</Month>\n                <Day>09</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Mol Pharm</MedlineTA>\n            <NlmUniqueID>101197791</NlmUniqueID>\n            <ISSNLinking>1543-8384</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">64Cu</Keyword>\n            <Keyword MajorTopicYN="N">GE11 peptide</Keyword>\n            <Keyword MajorTopicYN="N">colorectal cancer</Keyword>\n            <Keyword MajorTopicYN="N">epidermal growth factor receptor (EGFR)</Keyword>\n            <Keyword MajorTopicYN="N">polymeric micelles</Keyword>\n            <Keyword MajorTopicYN="N">positron emission tomography (PET)</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32233491</ArticleId>\n            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b01043</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'